Myongji Hospital launches MJ Vaccine Institute
Myongji Hospital Chairman Lee Wang-jun (fifth from left) and key members of MJ Vaccine Institute pose for photographers after holding a symposium to celebrate the launch of the institute at the hospital in Goyang, Gyeonggi Province, on Wednesday.
Myongji Hospital established MJ Vaccine Institute and held the first Covid-19 vaccine symposium to celebrate its launch on Wednesday.
The hospital, which distinguished itself as one of the centers to treat Covid-19, revealed its vision for the research and development of the Covid-19 vaccine based on its accumulated clinical experiences.
Leading the MJ Vaccine Institute will be Professor Kim Kwang-nam, who served as the head of the hospital’s Vaccination Task Force Team (TFT), Professor Lee Hyo-suk, who led Korea’s first development of infection vaccine while serving as the director of Liver Research Institute at Seoul National University and the chairman of Korean Association for the study of the Liver (KASL), and Professor Choi Kang-won who served as the chairman of the Korean Society of Infectious Diseases (KSID).
Also joining are professors at the hospital’s laboratory medicine and infectious diseases departments, Professor Park Sang-cheol, an expert in big data and artificial intelligence, and the professors at Myongji Hospital’s New Horizon Anti-cancer Research Institute, discussing the R&D strategy of Covid-19 vaccine.
“MJ Vaccine Institute, while making the most of its strength as an in-house clinical institution of our hospital, will promptly cooperate with various companies and research institutions to make best efforts for developing new platform technologies of mRNA(messenger ribonucleotide monomer) vaccine,” Myongji Hospital Chairman Lee Wang-jun said. “This institute will seek to serve as the driving force of translational research for vaccine development.”
At the Covid-19 vaccine symposium held online, Myongji Hospital professors presented their Covid-19 vaccine studies.
Professor Lee Ki-deok of the Department of Infectious Diseases presented the results of “Research on Covid-19 Vaccine Antibody Titer” conducted on the medical staff.
As the result of a cohort study of Pfizer and AstraZeneca vaccines, the Pfizer vaccine produced 99 percent of antibodies in three weeks after the first vaccination dose, while the AZ vaccine produced 98 percent of antibodies in eight weeks. After the second jabs, both vaccines made 100 percent of antibodies in two weeks. In the case of neutralizing antibodies, 87 percent were found in the Pfizer vaccine, and 66 percent were found in the AZ vaccine after the first vaccination. After the second vaccination, 100 percent of neutralizing antibodies were found in the Pfizer group and 98 percent in the AZ group.
“The research results were proven through Real World data at the clinical field. The study found that sufficient titer of antibody is produced after the second vaccination regardless of the vaccines,” Professor Lee said. “Myongji Hospital will go ahead with its tracer study through cohort. The change in antibody titer after vaccination will be observed every three months.”
Professor Lim Jae-gyun of the Laboratory Medicine Department unveiled the study results “The changes in antibody titer of naturally infected after Covid-19 vaccination” conducted on two nurses infected at the hospital’s Covid-19 hospital ward.
According to the study, in the case of people recovering from natural Covid-19 infection, a booster shot can produce 100 percent of antibodies. The research provided a policymaking hint that giving only one vaccine shot can sufficiently prevent effects in recovered people.
Also presented at the workshop were studies titled “Adverse reactions after Covid-19 vaccination” and “Research on the duration of antibodies after Covid-19 vaccination.”
“We plan to host a follow-up symposium shortly to provide live information on mRNA vaccine development and product, and also reports on succeeding research on the duration of antibodies after Covid-19 vaccination,” said Professor Kim Kwang-nam, director of MJ Vaccine Institute.
|95||Myongji Hospital opens Covid-19 home care support center||관리자||21-11-24||1|
|94||Myongji Hospital\'s telemedicine service for overseas Koreans passes regulatory sandbox||관리자||21-11-18||1|
|93||Myongji Hospital builds integrated Covid-19 home treatment system||관리자||21-10-22||1|
|92||Myongji Hospital to transfer advanced medical technology to Uzbekistan||관리자||21-10-05||1|
|91||Myongji Hospital to provide dementia screening for seniors||관리자||21-10-05||1|
|90||Myongji offers speedy, comfy Covid-19 test at Incheon airport||관리자||21-09-24||1|
|89||Myongji Hospital opens Covid-19 test center at Incheon International Airport||관리자||21-09-15||2|
|88||‘A single jab produced sufficient antibodies for Covid-19 survivors’||관리자||21-09-07||1|
|87||Myongji Hospital to hold dementia forum on Sept. 9||관리자||21-09-02||1|
|86||Myongji Hospital speeds up efforts to become biomedical hub||관리자||21-09-02||1|
|85||Myongji Hospital launches MJ Vaccine Institute||관리자||21-08-12||3|
|84||Myongji Hospital to provide healthcare support for Koreans in Indonesia||관리자||21-08-12||1|
|83||Myongji Hospital establishes 3 post-Covid-19 strategies||관리자||21-07-07||2|
|82||Myongji Hospital to participate in K-Bio Lab Hub construction project||관리자||21-06-21||1|
|81||Myongji Hospital expands healthcare service to Koreans in Africa, Mideast||관리자||21-05-26||2|